The advancing development in bioprocessing equipment by incorporating single-use technology prompted various pharmaceutical manufacturers to use cleanable or single-use systems. The Asia-Pacific single use system in biopharma market is growing at an astronomical rate due to the launch of innovative treatment solutions for cancer, autoimmune, cardiovascular & infectious diseases, rising investment toward biopharmaceutical industry and considerable adoption of the single-use systems in order to reduce cross contamination and increase efficiency and safety.
According to MarkNtel Advisors’ research report titled “Asia-Pacific Single Use System in Bio-Pharma Market Analysis, 2020”, the Asia-Pacific Single Use System in Bio-Pharma market is anticipated to grow at a considerable CAGR of around 12% during 2020-25. Based on bioprocessing, the small-scale segment acquired the considerable market share in 2019 owing to the rising adoption of single-use technology among small biotechnology start-ups and biopharmaceutical enterprises as it provides safety, flexibility, reduced capital, and operating costs.
“Asia-Pacific Single Use System in Bio-Pharma Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and growth opportunities available for Single Use System in Bio-Pharma providers across the region. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.
China Exhibited the Majority Market Share
China acquired the majority market share in the Asia-Pacific Single Use System in Bio-Pharma market in 2019. The growth is attributed to significant growth in biopharma technology, growing adoption single-use technologies (SUTs) for bioprocessing to help the patients access new forms of therapeutics, and escalating presence of international players for manufacturing single-use products in the country.
Moreover, Japan is anticipated to foresee high growth over the forecast period on an account of subsequent rise in the need for cost-effective modular bioprocessing facilities and launch of new products and increasing government expenditure for the development of the pharmaceutical industry. Thus, this is strongly contributing toward the market growth of the Single Use System in Biopharma in the forthcoming period as stated in the MarkNtel Advisors’ research report “Asia-Pacific Single Use System in Bio-Pharma Market Analysis, 2020”.
According to MarkNtel Advisors, the key players with a considerable market share in the Asia-Pacific Single Use System in Bio-Pharma market include GE Healthcare, MilliporeSigma, Entegris, Pall Corporation, Eppendorf, Corning, Thermo Fisher Scientific, Sartorius, PBS Biotech, Merck KGaA, Saint Gobain, Danaher Corp., Parker Hannifin Corp, and Kuhner, Rentschler Biopharma etc.
Key questions answered in the study